©2024 Stanford Medicine
In Vivo Characterization of Macrophages in Pediatric Patients With Malignant Brain Tumors Using Ferumoxytol-enhanced MRI
Not Recruiting
Trial ID: NCT03179449
Purpose
This pilot early phase I trial studies how well ferumoxytol-enhanced magnetic resonance
imaging (MRI) correlates with inflammatory (macrophage) responses in pediatric patients with
malignant brain tumors. If there is good correlation, ferumoxytol-enhanced MRI can serve as a
noninvasive imaging biomarker of inflammation.
Official Title
MR Imaging of Inflammatory Responses in the Central Nervous System With Ferumoxytol-Enhanced MRI (Pediatric Brain Tumor Protocol)
Stanford Investigator(s)
Michael Iv
Clinical Professor, Radiology
Eligibility
Inclusion Criteria:
- Any patient with suspected malignant brain tumor on diagnostic MR imaging who will
undergo a resection
Exclusion Criteria:
- Informed consent cannot be obtained either from the patient or legal representative
- Severe coexisting or terminal systemic disease that may interfere with the conduct of
the study
- Contraindication to MRI (metal implants)
- Hemosiderosis/hemochromatosis
- Iron overload from any cause (not just hemosiderosis or hemochromatosis), even if
secondary to frequent blood transfusions, severe chronic hemolysis, excess dietary or
parenteral iron, or any other etiology
- Known hypersensitivity to ferumoxytol or any of its components
- Pregnant patients
Intervention(s):
diagnostic test: Diagnostic (ferumoxytol-enhanced MRI)
procedure: Surgery
drug: Ferumoxytol
other: Tissue Analysis
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Paymon Rezaii
650-743-8336